NASDAQ:HROW Harrow (HROW) Stock Price, News & Analysis $41.28 +1.20 (+2.99%) (As of 10:46 AM ET) Add Compare Share Share Today's Range$40.09▼$41.5050-Day Range$17.65▼$40.0852-Week Range$7.60▼$41.50Volume221,366 shsAverage Volume490,808 shsMarket Capitalization$1.46 billionP/E RatioN/ADividend YieldN/APrice Target$40.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Harrow alerts: Email Address Harrow MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside0.2% Downside$40.00 Price TargetShort InterestBearish15.38% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.46Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.38) to $0.97 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.58 out of 5 starsMedical Sector876th out of 924 stocksPharmaceutical Preparations Industry407th out of 426 stocks 1.5 Analyst's Opinion Consensus RatingHarrow has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageHarrow has only been the subject of 3 research reports in the past 90 days.Read more about Harrow's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted15.38% of the outstanding shares of Harrow have been sold short.Short Interest Ratio / Days to CoverHarrow has a short interest ratio ("days to cover") of 9.9.Change versus previous monthShort interest in Harrow has recently decreased by 2.33%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldHarrow does not currently pay a dividend.Dividend GrowthHarrow does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HROW. Previous Next 2.5 News and Social Media Coverage News SentimentHarrow has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Harrow this week, compared to 2 articles on an average week.Search InterestOnly 9 people have searched for HROW on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days.MarketBeat Follows9 people have added Harrow to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Harrow insiders have not sold or bought any company stock.Percentage Held by Insiders13.67% of the stock of Harrow is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.76% of the stock of Harrow is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harrow's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Harrow are expected to grow in the coming year, from ($0.38) to $0.97 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harrow is -44.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harrow is -44.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarrow has a P/B Ratio of 19.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Harrow's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report About Harrow Stock (NASDAQ:HROW)Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Read More HROW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HROW Stock News HeadlinesAugust 21 at 5:23 AM | seekingalpha.comBorrowing Cash To Burn It: The Curious Case Of HarrowAugust 16, 2024 | seekingalpha.comHarrow: Bulls On ParadeAugust 22, 2024 | Insiders Exposed (Ad)$5k to $1.3m in just 3 tradesIt doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.August 13, 2024 | americanbankingnews.comHarrow (NASDAQ:HROW) Price Target Increased to $45.00 by Analysts at Craig HallumAugust 13, 2024 | americanbankingnews.comHarrow (NASDAQ:HROW) Price Target Raised to $50.00 at B. RileyAugust 10, 2024 | lse.co.ukHarrow Share Price (HROW.US)August 9, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Outset Medical (OM), Certara (CERT) and Harrow Health (HROW)August 9, 2024 | wsj.comHarrow Inc.August 22, 2024 | Insiders Exposed (Ad)$5k to $1.3m in just 3 tradesIt doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.August 9, 2024 | seekingalpha.comHarrow, Inc. (HROW) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | benzinga.comUnpacking the Latest Options Trading Trends in HarrowAugust 9, 2024 | msn.comHarrow Health, Inc. (NASDAQ:HROW) Q2 2024 Earnings Call TranscriptAugust 8, 2024 | seekingalpha.comHarrow, Inc. 2024 Q2 - Results - Earnings Call PresentationAugust 8, 2024 | finanznachrichten.deHarrow Health, Inc. Announces Second Quarter 2024 Financial ResultsJuly 31, 2024 | markets.businessinsider.comHarrow Health’s Strong Market Performance and Growth Prospects Justify Buy RatingJuly 3, 2024 | benzinga.comTop 3 Health Care Stocks That May Crash This QuarterJune 24, 2024 | seekingalpha.comHarrow Successfully Manufactures Triesence; Management Credibility SoarsJune 20, 2024 | businesswire.comHarrow Provides TRIESENCE® Relaunch UpdateSee More Headlines Receive HROW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harrow and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2023Today8/21/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HROW Previous SymbolNASDAQ:HROW CUSIPN/A CIK1360214 Webwww.harrowinc.com Phone(615) 733-4730Fax858-345-1745Employees182Year FoundedN/APrice Target and Rating Average Stock Price Target$40.00 High Stock Price Target$50.00 Low Stock Price Target$25.00 Potential Upside/Downside-0.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-24,410,000.00 Net Margins-21.78% Pretax Margin-20.71% Return on Equity-40.59% Return on Assets-8.93% Debt Debt-to-Equity Ratio3.18 Current Ratio2.60 Quick Ratio2.43 Sales & Book Value Annual Sales$154.15 million Price / Sales9.20 Cash FlowN/A Price / Cash FlowN/A Book Value$2.01 per share Price / Book19.94Miscellaneous Outstanding Shares35,382,000Free Float30,545,000Market Cap$1.42 billion OptionableOptionable Beta0.77 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Mark L. Baum J.D. (Age 49)CEO & Chairman Comp: $1.07MMr. Andrew R. Boll C.F.A. (Age 40)C.M.A., CFA, CMA, CFO & Corp. Sec. Comp: $716.73kDr. Robert J. Kammer D.D.S. (Age 73)Special Advisor Comp: $91.88kMr. John P. Saharek MBA (Age 62)Chief Commercial Officer Comp: $621.92kJamie WebbDirector of Communications & Investor RelationsDr. Dennis E Saadeh Pharm.D.Chief of Formulation StrategyMr. Andrew LivingstonChief Innovation OfficerMs. Kim BarrattChief Talent OfficerMore ExecutivesKey CompetitorsAVEO PharmaceuticalsNASDAQ:AVEOKindred BiosciencesNASDAQ:KINLifeVantageNASDAQ:LFVNMadrigal PharmaceuticalsNASDAQ:MDGLOrganon & Co.NYSE:OGNView All CompetitorsInsiders & InstitutionsSusquehanna International Group LLPSold 3,000 shares on 8/16/2024Ownership: 0.000%Creative PlanningBought 14,500 shares on 8/16/2024Ownership: 0.083%Millennium Management LLCSold 20,941 shares on 8/15/2024Ownership: 0.389%Deerfield Management Company L.P. Series CBought 9,105 shares on 8/15/2024Ownership: 0.072%The Manufacturers Life Insurance Company Bought 567 shares on 8/15/2024Ownership: 0.033%View All Insider TransactionsView All Institutional Transactions HROW Stock Analysis - Frequently Asked Questions How have HROW shares performed this year? Harrow's stock was trading at $11.20 on January 1st, 2024. Since then, HROW stock has increased by 257.9% and is now trading at $40.08. View the best growth stocks for 2024 here. How were Harrow's earnings last quarter? Harrow, Inc. (NASDAQ:HROW) announced its quarterly earnings results on Monday, November, 13th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by $0.12. The firm's revenue was up 50.1% compared to the same quarter last year. Who are Harrow's major shareholders? Top institutional investors of Harrow include Renaissance Technologies LLC (0.87%), Rice Hall James & Associates LLC (0.72%), Westside Investment Management Inc. (0.59%) and Susquehanna International Group LLP. Insiders that own company stock include Opaleye Management Inc, Mark L Baum, Andrew R Boll, Martin A Makary, Richard L Md Lindstrom and Horn R Lawrence Van. View institutional ownership trends. How do I buy shares of Harrow? Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Harrow own? Based on aggregate information from My MarketBeat watchlists, some other companies that Harrow investors own include NVIDIA (NVDA), Aldeyra Therapeutics (ALDX), OPKO Health (OPK), QUALCOMM (QCOM), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE) and CymaBay Therapeutics (CBAY). This page (NASDAQ:HROW) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harrow With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
